Skip to content

Chart Industries GTLS Cumulative Gross Losses and Impairments

Cumulative Gross Losses and Impairments at other companies

SPX Technologies logo
SPX TechnologiesSPXC

Segments

By segment

See full
Heat Transfer Systems$49.3M0.0%
Specialty Products$35.8M0.0%
Cryo Tank Solutions$23.5M0.0%
Repair, Service & Leasing$20.4M0.0%

Other financials

Income statement

See full
Revenue$884.8M-11.7%
Gross profit$251.4M-26.0%
Operating income$52.6M-65.5%
Net income-$17.1M-135%
EPS (diluted)-$0.36-138%

Balance sheet

See full
Cash & equivalents$269.4M-9.6%
Total debt$3.9B+1.9%
Total equity$3.2B+5.3%
Total assets$9.7B+4.1%

Cash flow

See full
Operating cash flow-$248.0M-313%
CapEx$24.8M+23.4%
Free cash flow-$272.8M-241%

Valuation

See full
Market cap$9.96B+50.0%
Enterprise value$13.59B+33.6%
P/S2.4×+0.8×

Profitability

See full
Gross margin32.5%-1.3pp
Operating margin6.2%-10.1pp
Net margin-0.6%-6.7pp
FCF margin0.2%-10.3pp

Returns & leverage

See full
Return on equity-0.8%-9.8pp
Debt / equity1.2×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Chart Industries in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Chart Industries’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Chart Industries's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Chart Industries's cumulative gross losses and impairments?
Chart Industries (GTLS) reported cumulative gross losses and impairments of $129M in Q1 2026.
How has Chart Industries's cumulative gross losses and impairments changed year-over-year?
Chart Industries's cumulative gross losses and impairments decreased by 0.0% year-over-year, from $129M to $129M.
What is the long-term trend for Chart Industries's cumulative gross losses and impairments?
Over 5 years (2020 to 2025), Chart Industries's cumulative gross losses and impairments has grown at a 0.0% compound annual growth rate (CAGR), from $129M to $129M.